Drug Discovery, Drug Research Editorial
-
Are KRAS Inhibitors Poised To Cure Cancer?
8/21/2023
The KRAS gene, a crucial component of cell signaling pathways involved in cell growth and division, is frequently mutated in various cancers. By targeting the gene, KRAS inhibitors aim to block the aberrant signaling that promotes cancer cell proliferation. Amgen's sotorasib became the first approved KRAS inhibitor, opening up an exciting field.
-
From Chips To Genes: The New Era Of Animal Models Transforming Drug Testing And Research
8/16/2023
The U.S. is at the forefront of the AI-based research trend surge to elevate the understanding of human physiology, testing potential therapies, and identifying disease mechanisms. Let's examine the five most promising innovative advancements in animal models, as well as key considerations for those working in the field.
-
“Intellectual Responsibility” In Drug Development
8/14/2023
All outsourced or not, “It's our product," says NervGen CEO Michael Kelly." We have an 'intellectual responsibility' as stewards to make sure we can get this through clinical trials and to patients as quickly as possible.”
-
How A CDMO Should Communicate A Form 483
8/9/2023
Form 483 – issued at the conclusion of an FDA inspection – is the perfect example to lend to a universal principle: Whatever is going on at a CDMO that might impact customers should be communicated to those customers. Here's a detailed analysis from industry professionals.
-
“Hiring” A CDMO For A Peptide To Repair Nerve Damage
8/7/2023
Things are moving relatively quickly at NervGen, but CEO Michael Kelly took time to speak about his outsourcing experiences and best practices for "hiring" external partners such as CDMOs.
-
ADC Executive Roundtable — Exploring Linker Technology
8/7/2023
A linker doesn't just act like a trailer hitch for antibody-drug conjugates. It's more like the driver steering the protein and payload toward the target, protecting it along the way. In the second and final part of a Q&A series, three biotech CEOs unpack exciting developments in ADC linker technology.
-
Japan’s Global Lessons In Outsourcing
8/2/2023
Chief Editor Louis Garguilo's first experiences in outsourcing involved Japan, when Japan Pharma considered offshore CDMOs as too risky. He recently took a trip to Tokyo to report on the state of the biopharma-CDMO market there today.
-
ADC Executive Roundtable — Perfecting The Payload And Navigating The Regulatory Landscape
7/28/2023
In a roundtable Q&A, three ADC company executives, Philipp Spycher of Araris, Dan O'Connor of Ambrx, and Radek Špíšek of SOTIO Biotech, dig into the latest developments in drug-antibody ratios. They also discuss the challenges they face when working with regulators for this complex yet promising modality.
-
5 Promising Applications Of RNA Therapeutics
7/28/2023
Ribonucleic acid (RNA), once considered a mere messenger molecule, has now emerged as a versatile tool in the development of novel therapies. In this article, we will delve into the world of RNA therapeutics, exploring their potential and five applications that could impact the future of medicine.
-
How Can Genetic Tuning Expand the Reach of Genetic Medicine?
7/26/2023
Epigenome editing, or genetic tuning, is an innovative molecular technology that fine-tunes the expression of genes to a therapeutically appropriate dosage, effectively expanding the reach of genetic medicine beyond the binary on-and-off switches of prior methods. Let's examine this more closely.